Clinical trials: H1N1/Influenza Infection
H1N1 Influenza Virus, Chronic Pulmonary Disease
Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus
This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvanted versus non-adjuvanted formulations of…
- Conditions
- H1N1 Influenza Virus, Chronic Pulmonary Disease, Chronic Heart Disease, Diabetes Mellitus
- Trial name
- NCT01032395
- Testing
- Focetria®, Fluad®, Begrivac®
- Where
- 2 sites in Brazil
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- Chiltern Pesquisa Clinica Ltda
Influenza, Human
Intramuscular CodaVax-H1N1 in Healthy Adults
This study is a Phase 1, 2-part, randomised, double-blind, controlled, clinical trial to evaluate the safety and immune response of CodaVax-H1N1 in healthy adults aged 18 to 49 years.
- Trial name
- NCT05223179
- Testing
- CODA-VAX H1N1, Flucelvax Quad, Saline
- Where
- Australia
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Codagenix, Inc
Influenza
Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults
A single center, randomized clinical trial is to be conducted in healthy adults (18-60 years) to evaluate the safety and immunogenicity and study the cell-mediated Immunity of Sinovac's H1N1 influenza A Vaccine (PANFLU.1) with…
- Trial name
- NCT01008137
- Testing
- H1N1 influenza A Vaccine (PANFLU.1), Trivalent Inactivated Influenza Vaccine (ANFLU)
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza A H3N2, Influenza A H1N1
Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A
Influenza, or the flu, is an infectious respiratory disease that can range in severity from mild to severe to even death. This study aims to evaluate a treatment for people who are hospitalized with the flu.
- Trial name
- NCT03315104
- Testing
- FLU-IGIV
- Where
- 55 sites in United States, Canada and 2 more
- Volunteers
- 65 people
- Sponsor
- Emergent BioSolutions
Influenza
Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study
The primary objective of this observational, comparative safety study is to evaluate the safety of the Novartis Pandemic Influenza A (H1N1) vaccine in pregnant women and their off spring, followed for up to 3 months of age as…
- Trial name
- NCT01037829
- Testing
- Non-intervention observational study
- Where
- 17 sites in Argentina, Italy and 1 more
- Volunteers
- 4,529 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
The purpose of this study is to characterize the safety and immune response of the H1N1 (swine) flu vaccines GSK2340274A and GSK2340273A in children 6 months to less than 9 years of age.
- Trial name
- NCT00976820
- Testing
- GSK2340274A, GSK2340273A
- Where
- 30 sites in United States, Canada
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Clinical Trial With Influenza A/H1N1 Vaccines
A single center, stratified, randomized and double-blind phase IV clinical trial is to be conducted in healthy elders (equal to or more than 61 years), adults (18-60 years), adolescents (12-17 years) and children (3-11 years) to…
- Trial name
- NCT00956111
- Testing
- split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose, split-virion, adjuvanted H1N1 vaccine of 15 μg per dose, split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose
- Where
- China
- Volunteers
- 1,614 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
Collection and Extraction of Respiratory Specimens
The study will be conducted with nasopharyngeal swab specimens collected prospectively from individuals suspected of having an acute respiratory tract infection caused by an Influenza virus.
- Trial name
- NCT01083511
- Where
- 3 sites in United States
- Volunteers
- 600 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Influenza
Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old
This study is designed to characterize the safety and immunogenicity of pandemic influenza (H1N1) candidate vaccines GSK2340274A and GSK234072A in children 3 to less than 10 years old.
- Trial name
- NCT01161160
- Testing
- GSK Biologicals' GSK2340274A (two different formulations), GSK Biologicals' - GSK2340272A
- Where
- 2 sites in Philippines, Thailand
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes
The objective of this study is to evaluate the immunogenicity and safety of one or two doses of GSK Biologicals' investigational influenza vaccine GSK2340272A, manufactured using two different processes, in adults aged 18 to 60…
- Trial name
- NCT00992511
- Testing
- GSK investigational vaccine GSK2340272A
- Where
- 4 sites in Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety Study of an Oral Vaccine to Prevent Seasonal Influenza
The purpose of this study was to demonstrate the safety and immunogenicity of an oral vaccine tablet to prevent seasonal influenza. The study was a placebo controlled, double blinded trial at a single site.
- Trial name
- NCT01688297
- Testing
- VXA-A1.1 Oral Vaccine
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Vaxart
Influenza
Safety and Immunogenicity Study of Fluval AB-Like Flu Vaccines With 3.5, 6, 9 or 15 μg HA in Adult and Elderly People
The purpose of this study is to determine the immunogenicity, tolerability and dose-effect relationship of one 0.5 mL intramuscular (IM) injection of four FLUVAL AB-like trivalent influenza vaccines containing either 3.5μgHA…
- Trial name
- NCT01408290
- Testing
- Vaccination with FAB-3511, Vaccination with FAB-6011, Vaccination with FAB-9011
- Where
- 4 sites in Hungary
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray
This study is being conducted to assess the safety, tolerability, and immunogenicity of the live-attenuated CodaVax-H1N1 influenza vaccine as compared to normal saline placebo both administered via intranasal spray to healthy…
- Trial name
- NCT04146623
- Testing
- CodaVax-H1N1 influenza vaccine
- Where
- Australia
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Codagenix, Inc
Influenza Caused by the Novel Influenza A (H1N1) Virus
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults
The purpose of the study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults.
- Trial name
- NCT00938639
- Testing
- CSL425
- Where
- Australia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)
This trial will assess the immunogenicity and safety elicited by the adjuvanted GSK Biologicals' influenza investigational vaccine GSK2340274A in healthy Japanese adults aged 20-64 years.
- Trial name
- NCT00989612
- Testing
- Influenza investigational vaccine GSK2340274A
- Where
- 2 sites in Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly
The purpose of the present study is to assess the immunogenicity, safety and reactogenicity of a two-dose schedule with vaccine GSK2340272A when co-administered with GSK Biologicals' Fluarix™ vaccine either at the time of first…
- Trial name
- NCT00968890
- Testing
- Pandemrix (Influenza vaccine GSK2340272A), Fluarix™
- Where
- 2 sites in Sweden
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Influenza Challenge Study of VIS410 in Healthy Volunteers
A phase 2 a study to assess the safety profile and the effect of VIS410 in healthy subjects after inoculation with influenza A virus (H1N1).
- Trial name
- NCT02468115
- Testing
- VIS410
- Where
- Belgium
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Visterra, Inc.
Influenza
Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)
This trial is designed to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 6 and 35 months.
- Trial name
- NCT00971321
- Testing
- Pandemic influenza vaccine GSK2340272A
- Where
- 5 sites in Spain
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Pandemic Influenza
Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine
The purpose of this observational study, which will be initiated as soon as the licensed H1N1 Pandemic Influenza Vaccine is used in a mass vaccination campaign, is to estimate the incidence of any medically-attended adverse…
- Trial name
- NCT00950456
- Testing
- H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)
- Where
- 17 sites in Austria
- Volunteers
- 3,216 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM
The aim of this study is to evaluate the immune response and the safety of one injection of FluarixTM/ Influsplit SSW® 2010/2011 or Pandemrix TM in subjects who had received a single Pandemrix TM dose at least 6 months preceding…
- Trial name
- NCT01160237
- Testing
- PandemrixTM, FluarixTM/ Influsplit SSW® 2010/2011
- Where
- 5 sites in Germany
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline